Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

近日，美国食品药品监督管理局（FDA）正式批准了由吉利德（Gilead）公司研发的全新艾滋病病毒（HIV）预防药物——来那卡帕韦（Lenacapavir）。这款 ...

红枫湾APP： firstwordpharma.com消息，默沙东 (也译为默克）的一款长效（ 每月1次 ） 口服 HIV预防药物也宣布进入后期（III期）试验阶段，即将为HIV PrEP（暴露前预防）再添新选择。

研究表明，在服用PrEP药物的人群中，能够坚持每日服药的比例只有约30-50%。现实中的依从性问题严重影响了PrEP的预防效果。来那帕韦的半年注射给药方式，很大程度上解决了这个问题,不仅可以提高用药依从性，还能减轻使用者的心理负担。

距离lenacapavir用于HIV预防在美国获批仅8个工作日，这一国际领先的创新药物就在博鳌乐城实现了“全球同步”准入，以“零时差”完成从海外获批到 ...

Although Uganda participated in a groundbreaking trial for Lenacapavir—an injectable drug proven effective in preventing ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

The introduction of a revolutionary drug, Lenacapavir, is poised to alter the landscape of healthcare across sub-Saharan ...